Myths and mysteries surrounding bacillus calmette-guérin therapy for bladder cancer

European Urology

Volumn 65, Issue 2, 2014, Pages 267-269

  Kamat, Ashish M ^a   Porten, Sima ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MITOMYCIN;

BCG VACCINATION; CANCER PATIENT; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); NON MUSCLE INVASIVE BLADDER CANCER; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84891835926     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.10.016     Document Type: Editorial

References (11)

1. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
2. R.J. Sylvester, M.A. van der, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
3. R.J. Sylvester, A.P. van der Meijden, J.A. Witjes, and K. Kurth Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials J Urol 174 2005 86 91 discussion 91-2
4. P.U. Malmstrom, R.J. Sylvester, and D.E. Crawford et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
5. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 2000 1124 1129
6. S. Hinotsu, H. Akaza, and S. Naito et al. Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer BJU Int 108 2011 187 195
7. R.A. Badalament, H.W. Herr, and G.Y. Wong et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer J Clin Oncol 5 1987 441 449
8. M.A. Hudson, T.L. Ratliff, D.P. Gillen, E.O. Haaff, S.M. Dresner, and W.J. Catalona Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial J Urol 138 1987 295 298
9. J. Palou, P. Laguna, F. Millan-Rodriguez, R.R. Hall, J. Salvador-Bayarri, and J. Vicente-Rodriguez Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors J Urol 165 2001 1488 1491
10. J. Oddens, M. Brausi, and R. Sylvester et al. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance Eur Urol 63 2013 462 472
11. J.A. Witjes, J. Palou, and M. Soloway et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS) BJU Int 112 2013 742 750